Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awdur:	Monica M. Mita (21585118) (author)
Awduron Eraill:	Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Cyhoeddwyd:	2025
Pynciau:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg